ClinicalTrials.gg
Not yet recruitingNCT05202990T-FOREUpdated May 6, 2026

Oral Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis

A Phase 2 interventional study of Fecal Microbiota Transplantation by Stool capsules and Fecal Microbiota Transplantation by Intra-rectal enemas in Pediatric Ulcerative Colitis in Remission, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 3 sites in France. Open to participants aged 8 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, 1 of them phase 3. Colitis, Ulcerative · Assistance Publique - Hôpitaux de Paris.

Started
2026
with 2 others
Phase 2
3 of 10
2 open now
Registered
6th of 10
by date

Among the 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris, this one is one of 3 that started in 2026, is one of 3 in phase 2, and was the 6th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

6 of the 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether FMT by frozen stool capsules in pediatric UC patients in remission after corticosteroid treatment, can modify their dysbiotic gut microbiota by increasing the richness of their microbiota at 6 months.

Read the detailed description

Ulcerative colitis (UC) is characterized by chronic inflammation of the colon of undetermined origin. Their incidence is increasing dramatically in the paediatric population.

Pediatric-onset inflammatory bowel disease (IBD) is characterized by a greater severity than adult IBD. Although great progress has been made in recent years, the pathogenesis of IBD is not fully elucidated. During UC, an imbalance in the composition of gut microbiota, called "dysbiosis", has been identified. This dysbiosis is notably characterized by an increased proportion of pro-inflammatory microorganisms and a decreased proportion of anti-inflammatory microorganisms. The current treatments used in IBD mainly target the immune system through immunosuppressants, and help to shorten flairs and prevent recurrences, but there is no curative treatment.

From a therapeutic point of view, the correction of this dysbiosis is thus an attractive approach. Until now, efficacy of microbiome-based therapies such as probiotics or antibiotics has been disappointing in IBD. Fecal microbiota transplantation (FMT) consists of the administration of fecal material from a donor into the intestinal tract of a recipient to change their microbiota composition and restore healthy conditions. FMT has been successfully used for many years for the treatment of Clostridioides difficile infection. Recent studies seem to show a benefit of FMT in UC.

The investigator's main hypothesis is that the replacement of a dysbiotic microbiota by a 'healthy' microbiota by FMT can modify the richness of UC patient's microbiota and has a positive impact on the disease course.

Once steroid-induced remission will be achieved, patients will be included and randomised to receive either FMT by frozen stool capsules or enemas. They will receive 3 doses at 0, 1 and 2 months. They will be followed for one year with stool samples collected every 3 months. Clinical and laboratory data will be collected.

03

Conditions studied

  • Pediatric Ulcerative Colitis in Remission

Browse trials for

Keywords

  • Ulcerative Colitis
  • Pediatric Onset Inflammatory Bowel Disease
  • Microbiota
  • Fecal Microbiota Transplantation
  • Stool capsule
  • Intra-rectal enemas
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 8 to 17 years old
  • Ulcerative colitis (UC), whatever the extent, except isolated proctitis (\<5 cm), diagnosed for more than 3 months according to the usual clinical, biological and endoscopic criteria
  • Moderate active UC defined by a PUCAI score > 35 and responding to treatment with a PUCAI score \<10 at enrollment
  • Treatment of UC (5-ASA, , biotherapies) stable for more than 3 months
  • Patient able to swallow test capsules
  • For girls of childbearing age:

    • To have a negative blood (or urine) pregnancy test
    • To agree to use a reliable method from visit 1 until the end of the research
  • Patient with health insurance
  • Informed written consent form signed by both parents or by the person (s) with parental authority

Exclusion criteria

Exclusion Criteria for patients:

  • isolated proctitis (\<5 cm)
  • Being on enteral nutrition
  • Have received antibiotic or antifungal treatment in the 4 weeks prior to enrollment
  • Having a Clostridioides difficile infection in the 4 weeks prior to enrollment;
  • Being pregnant or breastfeeding, or have a positive pregnancy test;
  • Have a to colonoscopy or general anaesthesia
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Fecal Microbiota Transplantation by Stool capsules

    Patients receiving fecal microbiota transplantation from a healthy donor in 3 times after inclusion and randomisation (Month 0 - Month 1 - Month 2) using frozen stool capsules

    Drug: Fecal Microbiota Transplantation by Stool capsules

  • Experimental
    Fecal Microbiota Transplantation by enema

    Patients receiving fecal microbiota transplantation from a healthy donor in 3 times after inclusion and randomisation (Month 0 - Month 1 - Month 2) using frozen stool enemas.

    Drug: Fecal Microbiota Transplantation by Intra-rectal enemas

Interventions

  • DrugFecal Microbiota Transplantation by Stool capsules

    After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia. The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces).

    Also known as: UC treatment

  • DrugFecal Microbiota Transplantation by Intra-rectal enemas

    After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia. The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas.

    Also known as: UC Treatment

06

What researchers measure

Primary outcomes

  1. Success of FMT with frozen stool capsules defined by an increase in the richness of the recipient's microbiota at 6 months.

    Success of FMT is defined by an increase in the richness of the recipient's microbiota at 6 months. Microbiota richness will be evaluated by measuring the alpha diversity of the microbiota using Shannon index. The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the recipient microbiota at M0 and the recipient microbiota at M6.

    Time frame: 6 months after the first Fecal Microbiota Transplantation (FMT)

Secondary outcomes

  1. Success of FMT with frozen stool capsules defined by an increase in the richness of the recipient's microbiota at 12 months

    The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the recipient microbiota at M0 and the recipient microbiota at M12.

    Time frame: 12 months after the first FMT

  2. Success of FMT by stool enema defined by an increase in the richness of the recipient's microbiota at 6 and 12 months

    The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the recipient microbiota at M0 and the recipient microbiota at M6 and M12

    Time frame: 6 and 12 months after the first FMT

  3. Success of FMT with frozen stool capsules on the change of recipient dysbiotic microbiota at 6 and 12 months

    The success of the FMT will be defined by a Bray Curtis (BC) Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.

    Time frame: 6 and 12 months after the first FMT

  4. Success of FMT by enema on the change of recipient dysbiotic microbiota at 6 and 12 months

    The success of the FMT will be defined by a Bray Curtis (BC) Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.

    Time frame: 6 and 12 months after the first FMT

  5. Success of FMT with frozen stool capsules on the richness and change of mucosal microbiota at 12 months

    The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the mucosal recipient microbiota at M0 and the mucosal recipient microbiota at M12

    Time frame: 12 months

  6. Success of FMT by enema on the richness and change of mucosal microbiota at 12 months

    The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the mucosal recipient microbiota at M0 and the mucosal recipient microbiota at M12

    Time frame: 12 months

  7. Success of FMT with frozen stool capsules on the change of mucosal recipient dysbiotic microbiota at 6 and 12 months

    The success of the FMT will be defined by a Bray Curtis (BC) Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.

    Time frame: 6 and 12 months after the first FMT

  8. Success of FMT by enema on the change of mucosal recipient dysbiotic microbiota at 6 and 12 months

    The success of the FMT will be defined by a Bray Curtis Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.

    Time frame: 6 and 12 months after the first FMT

  9. FMT with frozen stool capsules Feasibility

    Number of capsules intake, facility of capsules intake, tolerance, intake duration

    Time frame: At inclusion, 1 and 2 months after each FMT

  10. FMT by enema Feasibility

    Number of enemas, tolerance , enemas duration, difficulties related to the application of enemas

    Time frame: At inclusion, 1 and 2 months after each FMT

  11. Ulcerative colitis clinical relapse

    Defined as a Pediatric Ulcerative Colitis Activity Index (PUCAI) \> 35, number of relapses during the follow-up, treatments received during the follow-up

    Time frame: 6 and 12 months

  12. Ulcerative colitis Endoscopic relapse

    Defined as an Ulcerative Colitis Endoscopic Index of Severity (UCEIS) ≥ 2

    Time frame: 12 months

  13. Change of inflammatory blood markers from baseline to 12 months

    CRP, VS, Leucocytes levels

    Time frame: At inclusion, 6, 9 and 12 months

  14. Change of faecal calprotectin from baseline to 12 months

    Calprotectin level

    Time frame: At inclusion, 6, 9 and 12 months

  15. Change of patient's quality of life evaluated with IMPACT-3 questionnaire from inclusion until 12 months

    IMPACT-3 questionnaire of 35 closed questions - scale ranging from 1 to 5 for all answers - higher score suggesting better quality of life

    Time frame: At inclusion 2, 6, 9 and 12 months

  16. Incidence of adverse events

    Time frame: 26 months

07

Study locations

3 sites
  • Department of gastroenterology, Armand Trousseau Hospital
    Paris, 75012, France
    • Julie LEMALE, MD · Contactjulie.lemale@aphp.fr · 01 44 73 64 46
    • Julie LEMALE, MD · Principal investigator
  • Department of Pediatric Gastroenterology, Hepatology and Nutrition - Necker - Enfants Malades Hospital
    Paris, 75015, France
    • Bénédicte PIGNEUR · Contactbenedicte.pigneur@aphp.fr · 01 44 49 25 16
    • Bénédicte PIGNEUR, MD, PhD · Principal investigator
  • Department of Pediatric Gastroenterology, Robert Debré Hospital
    Paris, 75019, France
    • Alexis MOSCA, MD, PhD · Contactalexis.mosca@aphp.fr · 01 40 03 57 12
    • Alexis MOSCA, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jul 2028, 24 months later.

Of 45 non-industry phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 24 months is below that.

Counting every sponsor, half of 155 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2022
First posted
Jan 24, 2022
StartEst.
Jul 1, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Oct 1, 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05202990
Collaborators
MRSU 938 - Research Center of Saint Antoine, URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Jan 24, 2022
Start date
Jul 1, 2026 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
May 6, 2026

Study contacts

Bénédicte PIGNEUR, MD,PhD
Contact
benedicte.pigneur@aphp.fr
01 44 49 25 16 ext. +33
Gael Plastow, PhD
Contact
gael.plastow@aphp.fr
01 44 38 18 57 ext. +33
Bénédicte PIGNEUR, MD, PhD
principal investigator · AP-HP - Department of Pediatric Gastroenterology Hepatology and Nutrition - Necker - Enfants Malades Hospital
Harry SOKOL, MD, PhD
study director · AP-HP, Department of Gastroenterology and Nutrition - Saint Antoine Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion